Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408.
Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408.
复制标题
DOI：
10.1016/j.adro.2017.07.004
复制
发表时间：
2017-10
影响因子：
2.3
通讯作者：
Sandler H
中科院分区：
文献类型：
--
作者：
Nichols RC;Hu C;Bahary JP;Zeitzer KL;Souhami L;Leibenhaut MH;Rotman M;Gore EM;Balogh AG;McGowan D;Michalski J;Raben A;Rudoler S;Jones CU;Sandler H
我们回顾了在NRG肿瘤RTOG 9408上单独接受放射治疗（RT）的患者的睾丸激素变化。患者（T1b-T2b，前列腺特异性抗原<20 ng/mL）被随机分为单独RT和RT加4个月雄激素消融两组。血清睾酮（ST）水平在入组时、RT完成时以及RT后第一次随访3个月时进行调查。Wilcoxon签名秩检验用于比较随机分配到RT组的患者治疗前和治疗后的ST水平。在入选的2028名患者中，992名患者被随机分配接受单独的放疗，917名患者（92.4%）有基线ST值并完成了放疗。在这917名患者中，有447名和373名患者在放疗后立即和3个月的睾酮水平可获得。排除2例放疗后接受非方案激素治疗的患者，分别分析447例和371例患者。在所有患者中，RT结束时和随访3个月时ST值的中位变化为- 30.0 ng/dL （p5-p95; - 270.0 - 162.0; P < 0.05）。001)和−34.0毫微克/分升(p5-p95−228.0到160.0;P <。01),分别。前列腺癌的RT治疗与RT完成时ST的中位下降9.2%和RT后3个月的中位下降9.3%相关。这些变化具有统计学意义。
We reviewed testosterone changes for patients who were treated with radiation therapy (RT) alone on NRG oncology RTOG 9408. Patients (T1b-T2b, prostate-specific antigen <20 ng/mL) were randomized between RT alone and RT plus 4 months of androgen ablation. Serum testosterone (ST) levels were investigated at enrollment, RT completion, and the first follow-up 3 months after RT. The Wilcoxon signed rank test was used to compare pre- and post-treatment ST levels in patients who were randomized to the RT-alone arm. Of 2028 patients enrolled, 992 patients were randomized to receive RT alone and 917 (92.4%) had baseline ST values available and completed RT. Of these 917 patients, immediate and 3-month post-RT testosterone levels were available for 447 and 373 patients, respectively. Excluding 2 patients who received hormonal therapy off protocol after RT, 447 and 371 patients, respectively, were analyzed. For all patients, the median change in ST values at completion of RT and at 3-month follow-up were −30.0 ng/dL (p5-p95; −270.0 to 162.0; P < .001) and −34.0 ng/dL (p5-p95, −228.0 to 160.0; P < .01), respectively. RT for prostate cancer was associated with a median 9.2% decline in ST at completion of RT and a median 9.3% decline 3 months after RT. These changes were statistically significant.